Truist Financial
SRPT icon

Truist Financial’s Sarepta Therapeutics SRPT Stock Holding History

Truist Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,200
Closed -$413K – 2905
2025
Q4 		$413K Buy
19,200
+3,500
+22% +$73.8K ﹤0.01% 2149
2025
Q3 		$303K Buy
+15,700
New +$280K ﹤0.01% 2306

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truist Financial's SRPT Position: Q1 2026 in Review

Truist Financial reduced its Sarepta Therapeutics (SRPT) stake by 8.8% in Q1 2026, selling an estimated $25.9K and leaving 13,822 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

Truist Financial first reported a position in SRPT in Q2 2018 and has held it in 23 quarters since. The position peaked at $1.81M in Q3 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Truist Financial held 13,822 shares of Sarepta Therapeutics worth $301K as of Q1 2026.
  • Truist Financial sold 1,340 Sarepta Therapeutics shares in Q1 2026, an estimated $25.9K.
  • Sarepta Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2394 holding.
  • Truist Financial first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 23 quarters since.
  • Truist Financial's Sarepta Therapeutics position peaked at $1.81M in Q3 2020.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.